Cancer Drug Confirmatory Trials Should Be Initiated Early, FDA Says
Executive Summary
FDA is urging sponsors of cancer drugs undergoing accelerated approval to initiate confirmatory studies early to avoid problems in completing trials often seen after approval
You may also be interested in...
FDA Will Make Advisory Committee Review Of Accelerated Approvals An Annual Event
FDA plans to hold a yearly session with its Oncology Drugs Advisory Committee on cancer drugs granted accelerated approval as a means of holding sponsors' feet to the fire with regard to conducting confirmatory trials.
FDA Will Make Advisory Committee Review Of Accelerated Approvals An Annual Event
FDA plans to hold a yearly session with its Oncology Drugs Advisory Committee on cancer drugs granted accelerated approval as a means of holding sponsors' feet to the fire with regard to conducting confirmatory trials.
Pfizer Pulls Mylotarg For Safety 10 Years After Accelerated Approval
Although Pfizer's voluntary withdrawal of its acute myeloid leukemia therapy Mylotarg is the first complete withdrawal of an accelerated approval NDA, but as in other cases where the confirmatory trial fails to substantiate the initial signs of efficacy that supported the accelerated approval, FDA is not completely closing the door on access to the drug